

Doxycycline Plus Streptomycin Versus Ciprofloxacin Plus Rifampicin in Spinal Brucellosis

Submission date
22/03/2006

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
29/03/2006

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
13/10/2009

Condition category
Infections and Infestations

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Emine Alp

Contact details

Department of Infectious Disease
Erciyes University Medical School
Kayseri
Türkiye
38039
ealp@erciyes.edu.tr

Additional identifiers

Protocol serial number

04/131

Study information

Scientific Title

Study objectives

Ciprofloxacin plus rifampicin may be an alternative treatment regimen to doxycycline plus streptomycin in the treatment of spinal brucellosis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Yes, Approved by the Ethical Committee of Erciyes University, approval date: 4/05/2001, reference number: 04/131

Study design

An open, controlled and non-randomized trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Brucellosis is an infectious disease affecting multiple systems including vertebrae

Interventions

To compare the efficacy, adverse drug reactions, complications and cost of ciprofloxacin plus rifampicin versus doxycycline plus streptomycin in the treatment of spinal brucellosis

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Doxycycline, streptomycin, ciprofloxacin, rifampicin

Primary outcome(s)

1. Clinical efficacy of ciprofloxacin plus rifampicin in spinal brucellosis
2. The prevalence of relapses

Key secondary outcome(s)

The cost of the two regimens

Completion date

31/12/2004

Eligibility**Key inclusion criteria**

The patients diagnosed with spinal brucellosis between January 2002 to December 2004 were enrolled into two study groups consecutively

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Age less than 16 years
2. Pregnancy
3. Neurobrucellosis
4. Previous history of brucellosis and antimicrobial therapy and discontinuation of the therapy for any reason (allergy to any of the drugs, death, adverse reactions)

Date of first enrolment

01/01/2002

Date of final enrolment

31/12/2004

Locations**Countries of recruitment**

Türkiye

Study participating centre

Department of Infectious Disease

Kayseri

Türkiye

38039

Sponsor information**Organisation**

Erciyes University Medical School (Turkey)

ROR

<https://ror.org/047g8vk19>

Funder(s)

Funder type

University/education

Funder Name

The study was supported by Infectious Disease Clinic, Erciyes University Medical School (Turkey)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	11/04/2006		Yes	No